سعر كيبروليس 60مجم وريد فيال 2026

Carfilzomib 60 mg powder for solution for intravenous infusion (single vial), a proteasome inhibitor for relapsed multiple myeloma.

• Adults with multiple myeloma who have received at least one prior therapy, in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone.Population: AdultsEuropean Medicines Agency (EMA)
• Relapsed or refractory multiple myeloma after 1-3 prior lines in combination regimens (Kd, KRd, DKd, Isa-Kd), or as monotherapy after one or more lines (US label).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Hypersensitivity to the active substance or any excipient.International label, same product · European Medicines Agency (EMA)
• Women who are breast-feeding.International label, same product · European Medicines Agency (EMA)

• Cardiac toxicity (new or worsening heart failure, reduced LVEF, myocardial ischaemia), pulmonary toxicity (ARDS, acute respiratory failure, pulmonary hypertension), dyspnoea and hypertension including hypertensive crisis have occurred; monitor and interrupt or adjust as needed.International label, same product · European Medicines Agency (EMA)
• Female patients of childbearing potential must use effective contraception during and for one month after treatment; males for 3 months after if partner may become pregnant.International label, same product · European Medicines Agency (EMA)
• US: females of reproductive potential should use effective contraception during treatment and for 6 months after the last dose; males for 3 months.International label, same product · DailyMed (U.S. National Library of Medicine)

• Oral contraceptives and hormonal contraceptives with thrombosis riskEfficacy of oral contraceptives may be reduced and VTE risk is increased; use an alternative effective non-hormonal method.European Medicines Agency (EMA)
• P-glycoprotein substrates (e.g. digoxin, colchicine)Carfilzomib inhibits P-gp in vitro; caution with P-gp substrates.European Medicines Agency (EMA)

• No data in pregnant women; animal studies show reproductive toxicity and carfilzomib can cause foetal harm; do not use in pregnancy unless benefit outweighs risk. Lenalidomide combination requires its pregnancy prevention programme.International label, same product · European Medicines Agency (EMA)
• EU: breast-feeding is contraindicated during and for at least 2 days after treatment.International label, same product · European Medicines Agency (EMA)
• US: advise women not to breastfeed during treatment and for 2 weeks after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Carfilzomib: Tetrapeptide epoxyketone that irreversibly binds the N-terminal threonine active sites of the 20S proteasome, causing accumulation of polyubiquitinated proteins, cell-cycle arrest and apoptosis (EU SmPC 5.1).